SCHEMBL14239258

SCHEMBL14239258

CCOC(=O)c1noc(-c2ccc(N)cc2F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
PLAT P00750 1/20 0.41
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAOA P21397 1/20 0.40
ADORA3 P0DMS8 2/20 0.40
OPRK1 P41145 1/20 0.40
PRKCZ Q05513 1/20 0.39
KCNH2 Q12809 2/20 0.39
SLC26A6 Q9BXS9 4/20 0.39
ACKR3 P25106 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
IDO1 P14902 1/20 0.38
S1PR1 P21453 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19814674 0.88 ACKR3 (0.46) PLATOPRK1KCNH2SLC26A6ACKR3
SCHEMBL29775777 0.88 ACKR3 (0.46) PLATOPRK1KCNH2SLC26A6ACKR3
SCHEMBL15471922 0.88 OPRK1 (0.45) SMN1; SMN2PLATOPRK1KCNH2SLC26A6
SCHEMBL14167749 0.83 S1PR1 (0.42) SMN1; SMN2PLATLMNAOPRK1KCNH2
SCHEMBL15464775 0.83 PLAT (0.41) PLATOPRK1KCNH2SLC26A6NPC1
SCHEMBL14240125 0.81 NPC1 (0.45) SMN1; SMN2CYP3A4MAOAKCNH2ACKR3
SCHEMBL893135 0.81 S1PR1 (0.52) PLATOPRK1KCNH2SLC26A6S1PR1
SCHEMBL14239264 0.78 MAPT (0.43) LMNACYP1A2CYP3A4MAOAPRKCZ
SCHEMBL2300298 0.77 LMNA (0.44) SMN1; SMN2LMNACYP1A2CYP3A4MAOA
SCHEMBL26690781 0.77 PTGES (0.43) PLATLMNAOPRK1KCNH2SLC26A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012168315-A1 SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-13 WO disclosed